newsfilter
← Latest News
GlobeNewswire·

Cardiff Oncology Prices Oversubscribed $40 Million Underwritten Registered Direct Offering

SAN DIEGO, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ:CRDF) ("Cardiff Oncology" or the "Company"), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies